+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Aspirin for primary prevention of cardiovascular disease in diabetes



Aspirin for primary prevention of cardiovascular disease in diabetes



Journal of Diabetes Investigation 2019



Cardiovascular disease (CVD) is a major cause of morbidity and mortality in people with diabetes. Aspirin is commonly used in the treatment and prevention of CVD, and the effectiveness of aspirin for the secondary prevention of CVD is well established in people with or without diabetes. In contrast, the role of aspirin in primary prevention is still controversial as the cardiovascular benefit of aspirin may not outweigh the risk of haemorrhage. Even though diabetes raises cardiovascular risk which would suggest that aspirin could have a greater benefit, it remains uncertain whether there is a clear net benefit of aspirin in primary prevention of CVD in people with diabetes. This article is protected by copyright. All rights reserved.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066084995

Download citation: RISBibTeXText

PMID: 30637961

DOI: 10.1111/jdi.13006


Related references

Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?. Medical Journal of Australia 190(11): 614-615, 2009

Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. Diabetes & Vascular Disease Research 9(4): 243-244, 2013

Aspirin for primary prevention of cardiovascular disease events in diabetes: the balancing act?. Journal of the Royal College of Physicians of Edinburgh 48(4): 332-333, 2018

Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. Diabetes, Obesity & Metabolism 11(11): 997-1000, 2011

Preventing cardiovascular disease in patients with diabetes: use of aspirin for primary prevention. Current Cardiology Reports 17(3): 566-566, 2015

Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis. Diabetes Research and Clinical Practice 120(): 31-39, 2016

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opinion on PharmacoTherapy 11(9): 1459-1466, 2010

Review: current evidence shows no overall benefit of aspirin for primary prevention of cardiovascular disease in diabetes. Annals of Internal Medicine 152(8): Jc4-J10, 2010

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8(): 21-21, 2007

Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. Thrombosis and Haemostasis 104(6): 1085-1088, 2011

Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?. New Zealand Medical Journal 131(1484): 19-25, 2018

Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study. Diabetes Care 33(2): 317-321, 2010

Aspirin for primary prevention of cardiovascular events in diabetes. Diabetes Care 26(12): 3349-3350, 2003

The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. Clinical Pharmacology and Therapeutics 100(5): 500-512, 2016

Aspirin for primary prevention of cardiovascular events in people with diabetes. Journal of the American College of Cardiology 55(25): 2878-2886, 2010